Score Overview
Explore the 2021 public Archive ranking →
Where Evogene has ranked, year by year
Showing 10 years ranking history by Net Income Consistency.
Has not reached the top 50 on Net Income Consistency in any year we have ranked.
- EVGN
2020: 98.7% · 2021: 99.3% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-10-22 | $ 0.38 | — |
1 Year2025-10-22 | $ 1.27 | -70.40% |
5 Years2021-10-22 | $ 26.90 | -98.60% |
10 Years2016-10-21 | $ 61.10 | -99.38% |
| Period | Last Price2026-10-22 | 1 Year2025-10-22 | 5 Years2021-10-22 | 10 Years2016-10-21 |
|---|---|---|---|---|
| Price | $ 0.38 | $ 1.27 | $ 26.90 | $ 61.10 |
| Return | — | -70.40% | -98.60% | -99.38% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 1M | -$ 9M | $ 9M |
| 2025 | $ 3M | -$ 8M | $ 12M |
| 2024 | $ 5M | -$ 16M | $ 15M |
| 2023 | $ 2M | -$ 23M | $ 31M |
| 2022 | $ 1M | -$ 26M | $ 35M |
| 2021 | $ 930K | -$ 27M | $ 53M |
| 2020 | $ 1M | -$ 23M | $ 48M |
| 2019 | $ 753K | -$ 18M | $ 46M |
| 2018 | $ 1M | -$ 20M | $ 54M |
| 2017 | $ 3M | -$ 20M | $ 71M |
| 2016 | $ 6M | -$ 19M | $ 88M |
| 2015 | $ 11M | -$ 17M | $ 100M |
| 2014 | $ 14M | -$ 14M | $ 115M |
| 2013 | $ 17M | -$ 8M | $ 126M |
| 2012 | $ 17M | -$ 2M | $ 55M |
| 2011 | $ 14M | $ 645K | |
| 2010 |
Evogene fundamental performance
Between 2020 and 2025, revenue grew from $ 1M to $ 3M and net income went from -$ 23M to -$ 8M. Revenue increased in 3 of those 5 years; net income in 4.
Between 2015 and 2025, revenue declined from $ 11M to $ 3M and net income went from -$ 17M to -$ 8M. Revenue increased in 4 of those 10 years; net income in 6.
Evogene currently holds a 5-year HDB Score of 6.4 out of 10. How the HDB Score is calculated.
Membership
Continue EVGN’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 5,119 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
